2026-06-16T13:58:45Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/89942025-04-24T12:40:01Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968
00925njm 22002777a 4500
dc
Rondy, Marc
author
Gherasim, Alin Manuel
author
Casado, Itziar
author
Launay, Odile
author
Rizzo, Caterina
author
Pitigoi, Daniela
author
Mickiene, Aukse
author
Marbus, Sierk D
author
Machado, Ausenda
author
Syrjänen, Ritva K
author
Pem-Novose, Iva
author
Horváth, Judit Krisztina
author
Larrauri, Amparo
author
Castilla, Jesús
author
Vanhems, Philippe
author
Alfonsi, Valeria
author
Ivanciuc, Alina E
author
Kuliešė, Monika
author
van Gageldonk-Lafeber, Rianne
author
Gomez, Verónica
author
Ikonen, Niina
author
Lovric, Zvjezdana
author
Ferenczi, Annamária
author
I-MOVE+ hospital working group
author
Moren, Alain
author
2017
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
Euro Surveill. 2017 Oct;22(41).
10.2807/1560-7917.ES.2017.22.41.17-00645
1560-7917
1560-7917
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
29043961
http://hdl.handle.net/20.500.12105/8994
A(H3N2)
Influenza
Cases control
Elderly
Hospitalisation
Vaccine effectiveness
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season